Show simple item record

Willingness to use and preferences for long-acting injectable PrEP among sexual and gender minority populations in the southern United States, 2021–2022: cross-sectional study

dc.contributor.authorSchoenberg, Paige
dc.contributor.authorEdwards, O. Winslow
dc.contributor.authorMerrill, Leland
dc.contributor.authorMartinez, Cristian Acero
dc.contributor.authorStephenson, Rob
dc.contributor.authorSullivan, Patrick S.
dc.contributor.authorJones, Jeb
dc.date.accessioned2023-04-04T17:41:47Z
dc.date.available2024-04-04 13:41:45en
dc.date.available2023-04-04T17:41:47Z
dc.date.issued2023-03
dc.identifier.citationSchoenberg, Paige; Edwards, O. Winslow; Merrill, Leland; Martinez, Cristian Acero; Stephenson, Rob; Sullivan, Patrick S.; Jones, Jeb (2023). "Willingness to use and preferences for long-acting injectable PrEP among sexual and gender minority populations in the southern United States, 2021–2022: cross-sectional study." Journal of the International AIDS Society 26(3): n/a-n/a.
dc.identifier.issn1758-2652
dc.identifier.issn1758-2652
dc.identifier.urihttps://hdl.handle.net/2027.42/176073
dc.description.abstractIntroductionLong-acting injectable (LAI) pre-exposure prophylaxis (PrEP) for HIV prevention was approved by the U.S. Food and Drug Administration in 2021. LAI PrEP is more effective than oral PrEP. However, it is not clear whether the groups most at risk of HIV in the United States will use LAI PrEP. Willingness to use LAI PrEP and preference for LAI versus oral PrEP has not been reported for sexual and gender minority (SGM) people in the southern United States, where the HIV epidemic is concentrated. Our goal was to assess willingness to use LAI PrEP and preference for oral versus LAI PrEP among SGM people in the southern United States and to assess differences in willingness by demographics and sexual behaviour.MethodsWe conducted an online, cross-sectional survey of SGM people aged 15–34 years in the southern United States (n = 583). Participants reported willingness to use LAI PrEP and preferences for LAI PrEP versus daily oral PrEP. We assessed bivariate associations and adjusted prevalence ratios for the LAI-PrEP-related outcomes and key demographic and behavioural characteristics.ResultsOverall, 68% of all participants (n = 393) reported being willing to use LAI PrEP that provides protection against HIV for 3 months. Of those, most (n = 320, 81%) indicated a preference for using LAI PrEP, compared to a daily oral pill or no preference. Willingness to use LAI PrEP was more common among transgender and non-binary participants and participants who engaged in condomless anal intercourse in the last 6 months. Hispanic participants were more likely and non-Hispanic Black participants were less likely to report willingness to use LAI PrEP compared to non-Hispanic White participants.ConclusionsWillingness to use LAI PrEP was high among SGM people in the southern United States, although there were some important differences in willingness based on demographic characteristics. Decreased willingness to use LAI PrEP among groups who are disproportionately affected by the HIV epidemic, such as non-Hispanic Black SGM people, could exacerbate existing disparities in HIV incidence. LAI PrEP is an acceptable option among SGM populations in the southern United States, but strategies will be needed to ensure equitable implementation.
dc.publisherU.S. Food and Drug Administration
dc.publisherWiley Periodicals, Inc.
dc.subject.othertransgender people
dc.subject.othersexual and gender minority populations
dc.subject.otherpre-exposure prophylaxis
dc.subject.otherHIV
dc.subject.otherinjectable
dc.subject.othermen who have sex with men
dc.titleWillingness to use and preferences for long-acting injectable PrEP among sexual and gender minority populations in the southern United States, 2021–2022: cross-sectional study
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelMicrobiology and Immunology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/176073/1/jia226077.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/176073/2/jia226077_am.pdf
dc.identifier.doi10.1002/jia2.26077
dc.identifier.sourceJournal of the International AIDS Society
dc.identifier.citedreferenceMuller CJ, MacLehose RF. Estimating predicted probabilities from logistic regression: different methods correspond to different target populations. Int J Epidemiol. 2014; 43 ( 3 ): 962 – 70.
dc.identifier.citedreferenceFDA approves first injectable treatment for HIV pre-exposure prevention. U.S. Food and Drug Administration; 2021.
dc.identifier.citedreferenceCenters for Disease Control and Prevention. Preexposure prophylaxis for the prevention of HIV infection in the United States –2021 update clinical practice guideline. 2021. Accessed April 18, 2022. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf
dc.identifier.citedreferenceWray TB, Chan PA, Kahler CW, Simpanen EM, Liu T, Mayer KH. Vulnerable periods: characterizing patterns of sexual risk and substance use during lapses in adherence to HIV pre-exposure prophylaxis among men who have sex with men. J Acquir Immune Defic Syndr. 2019; 80 ( 3 ): 276 – 83.
dc.identifier.citedreferenceLandovitz RJ, Donnell D, Clement ME, Brett H,  Leslie C,  Lara C, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021; 385 ( 7 ): 595 – 608.
dc.identifier.citedreferenceLevy ME, Agopian A, Magnus M, Anthony R, Jenevieve O, Michael K, et al. Is long-acting injectable cabotegravir likely to expand PrEP coverage among MSM in the District of Columbia? J Acquir Immune Defic Syndr. 2021; 86 ( 3 ): e80 – 2.
dc.identifier.citedreferenceJohn SA, Whitfield THF, Rendina HJ, Parsons JT, Grov C. Will gay and bisexual men taking oral pre-exposure prophylaxis (PrEP) switch to long-acting injectable PrEP should it become available? AIDS Behav. 2018; 22 ( 4 ): 1184 – 89.
dc.identifier.citedreferenceGolub SA, Meyers K, Enemchukwu C. Perspectives and recommendations from lesbian, gay, bisexual, transgender, and queer/questioning youth of color regarding engagement in biomedical HIV prevention. J Adolesc Health. 2020; 66 ( 3 ): 281 – 87.
dc.identifier.citedreferenceCenters for Disease Control and Prevention. HIV surveillance report. 2020. Accessed July 6, 2022. https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html
dc.identifier.citedreferenceCenters for Disease Control and Prevention. HIV surveillance in urban and nonurban areas. 2018. Accessed March 26, 2021. https://www.cdc.gov/hiv/pdf/library/slidesets/cdc-hiv-surveillance-urban-nonurban-2018.pdf
dc.identifier.citedreferenceInstitute of Medicine (IOM). The health of lesbian, gay, bisexual, and transgender people: building a foundation for better understanding. National Academies Press; 2011.
dc.identifier.citedreferenceGengiah TN, Moosa A, Naidoo A, Mansoor LE. Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection. Int J Clin Pharm. 2014; 36 ( 1 ): 70 – 85.
dc.identifier.citedreferenceStephenson R, Rogers E, Mansergh G, Hirshfield S, Sullivan P. Intimate partner violence and preferences for pre-exposure prophylaxis (PrEP) modes of delivery among a sample of gay, bisexual, and other men who have sex with men. AIDS Behav. 2022; 26 ( 7 ): 2425 – 34.
dc.identifier.citedreferenceParsons JT, Rendina HJ, Whitfield TH, Grov C. Familiarity with and preferences for oral and long-acting injectable HIV pre-exposure prophylaxis (PrEP) in a national sample of gay and bisexual men in the U.S. AIDS Behav. 2016; 20 ( 7 ): 1390 – 9.
dc.identifier.citedreferenceWaldorf B, Kim A. The Index of Relative Rurality (IRR): US county data for 2000 and 2010. 2018.
dc.identifier.citedreferenceWaldorf BS. A continuous multi-dimensional measure of rurality: moving beyond threshold measures. Presented at: Selected Paper. 2006. Accessed April 18, 2022. https://ageconsearch.umn.edu/record/21383/files/sp06wa02.pdf
dc.identifier.citedreferenceJones J, Zlotorzynska M, Villarino X, Sanchez T. Where is rural? Examining the effect of rural classification method on disparities in HIV and STI testing uptake among men who have sex with men in the United States. AIDS Behav. 2022; 26: 2897 – 2906.
dc.identifier.citedreferenceFortenberry JD, McFarlane M, Bleakley A, Bull S, Fishbein M, Grimley DM, et al. Relationships of stigma and shame to gonorrhea and HIV screening. Am J Public Health. 2002; 92 ( 3 ): 378 – 81.
dc.identifier.citedreferenceTekeste M, Hull S, Dovidio JF, Safon CB, Blackstock O, Taggart T, et al. Differences in medical mistrust between black and white women: implications for patient–provider communication about PrEP. AIDS Behav. 2019; 23 ( 7 ): 1737 – 48.
dc.identifier.citedreferenceBogart LM, Ransome Y, Allen W, Higgins-Biddle M, Ojikutu BO. HIV-related medical mistrust, HIV testing, and HIV risk in the national survey on HIV in the black community. Behav Med. 2019; 45 ( 2 ): 134 – 42.
dc.identifier.citedreferenceJacobs EA, Rolle I, Ferrans CE, Whitaker EE, Warnecke RB. Understanding African Americans’ views of the trustworthiness of physicians. J Gen Intern Med. 2006; 21 ( 6 ): 642 – 47.
dc.identifier.citedreferenceCahill S, Taylor SW, Elsesser SA, Mena L, Hickson D, Mayer KH. Stigma, medical mistrust, and perceived racism may affect PrEP awareness and uptake in black compared to white gay and bisexual men in Jackson, Mississippi and Boston, Massachusetts. AIDS Care. 2017; 29 ( 11 ): 1351 – 8.
dc.identifier.citedreferenceSullivan PS, Satcher Johnson A, Pembleton ES, Stephenson R, Justice AC, Althoff KN, et al. Epidemiology of HIV in the USA: epidemic burden, inequities, contexts, and responses. Lancet. 2021; 397 ( 10279 ): 1095 – 106.
dc.identifier.citedreferenceCenters for Disease Control and Prevention. HIV surveillance report. 2019. Accessed April 18, 2022. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html
dc.identifier.citedreferenceMansergh G, Kota KK, Stephenson R, Hirshfield S, Sullivan P. Preference for using a variety of future HIV pre-exposure prophylaxis products among men who have sex with men in three US cities. J Int AIDS Soc. 2021; 24 ( 1 ): e25664.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.